One of the largest pharmaceutical companies in North Carolina is discontinuing a treatment produced in the state.

According to multiple media reports on Thursday, Pfizer Inc. (NYSE:PFE) has terminated the global development and ...

Ixinity (trenonacog alfa) can effectively prevent and controlled bleeds in young children with severe or moderately severe ...

Pfizer is pulling further away from the gene therapy field with its decision to discontinue hemophilia product Beqvez. | ...

The move comes weeks after Pfizer terminated its partnership with Sangamo Therapeutics for another hemophilia gene therapy.

Pfizer’s decision to halt further marketing of Beqvez is further sign of the sparse patient interest in gene therapies for ...

Pfizer said on Thursday it will stop global development and commercialization of its hemophilia gene therapy, Beqvez, citing ...

For about 35 years before 2010, Tanzania had only 2 Hematologists, and were all retired. In 2007, Dr Rwezaula and three other ...

Less than a year after approval, Pfizer said it plans to discontinue its hemophilia B gene therapy fidanacogene elaparvovec ...

NEW YORK/TOKYO -- Pfizer will end global development and commercialization of Beqvez, a gene therapy for hemophilia, Nikkei learned Thursday, after the drugmaker dropped its other similar treatment ...

Pfizer said on Thursday it will end global development of its hemophilia gene therapy, Beqvez, citing soft demand from ...

Pfizer (PFE) will end global development and commercialization of Beqvez, a gene therapy for hemophilia, Nikkei learned Thursday, after the ...